Verrica Pharmaceuticals Stock Price, News & Analysis

Verrica Pharmaceuticals (Nasdaq: VRCA) has announced a significant amendment to its Collaboration and License Agreement with Torii Pharmaceutical for launching a global Phase 3 clinical trial of YCANTH® to treat common warts. The company will receive an $8 million milestone payment in July 2025 for initiating the study, and an additional $10 million milestone payment upon YCANTH's approval for molluscum contagiosum in Japan, expected by end of 2025.

The agreement includes Torii funding the first $40 million of out-of-pocket costs for the global study, covering approximately 90% of the current clinical budget. The study targets common warts, which affects 22 million patients in the United States alone, with no current FDA-approved prescription therapies. Verrica plans to dose the first patient in the U.S. Phase 3 trial in Q4 2025.

Under the amended agreement, Verrica maintains ownership of global rights to YCANTH for all indications outside Japan. The companies will split the Phase 3 program costs 50/50, with Verrica repaying its portion through offsets against future royalties and transfer price payments from Torii. Additionally, Verrica will initiate a manufacturing transfer to Torii for YCANTH applicators for the Japanese market.

Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, announced its participation in the upcoming Jefferies Global Healthcare Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will deliver a presentation on Wednesday, June 4, 2025, at 4:20 pm ET.

The event will be accessible via live webcast through the company's website and a dedicated link. A replay will be available for 90 days following the presentation in the Investors/Presentations & Events section of www.verrica.com.

Verrica Pharmaceuticals (NASDAQ: VRCA) reported Q1 2025 financial results, highlighting record-breaking YCANTH sales with $3.4 million in revenue and over 10,000 dispensed applicator units, marking a 16.7% growth from Q4'24. The company's pipeline advances include completing an end-of-Phase 2 FDA meeting for VP-315 (basal cell carcinoma treatment) and progress toward a global Phase 3 program for common warts with partner Torii Pharmaceutical. Key financial metrics show a net loss of $9.7 million ($0.10 per share), improved from $20.3 million loss in Q1 2024. Operating expenses decreased significantly, with SG&A expenses down to $8.8 million from $16.3 million, and R&D expenses reduced to $2.3 million from $4.9 million. The company maintained $29.6 million in cash and cash equivalents as of March 31, 2025.

Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, has scheduled its Q1 2025 earnings conference call and webcast for May 13, 2025, at 4:30 p.m. ET. The company will discuss financial results for the quarter ending March 31, 2025, and provide corporate updates.

Participants can join via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) using conference ID: VERRICA. The webcast will be accessible through Verrica's investor relations website and will remain archived for 90 days after the event.

Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, announced its upcoming participation in the Citizens Life Sciences Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will deliver a presentation at the event.

The presentation is scheduled for Wednesday, May 7, 2025, at 3:00 pm ET and will take place at the New York Hilton Midtown. Interested parties can access a live webcast through the provided link or via the Investors/Presentations & Events section on Verrica's website. The presentation recording will remain available for 90 days after the event.

Verrica specializes in developing medications for skin diseases that require medical interventions, positioning itself as a key player in the dermatology therapeutics sector.

Verrica Pharmaceuticals (VRCA) reported significant growth in YCANTH® dispensed applicator units for Q1 2025, reaching 10,102 units - a 16.7% sequential increase from Q4 2024's 8,654 units.

The company attributes this growth to their recent commercial restructuring and normalized distribution inventory levels. With stabilized channel inventory, the dispensed units are expected to more closely track demand and gross revenue going forward.

The management highlighted that strong market access, normalized inventory levels, and a focused commercial team building relationships within dermatology and pediatric communities position YCANTH® for sustainable revenue growth. The company aims to establish YCANTH® as the standard treatment for molluscum contagiosum.

Verrica Pharmaceuticals (Nasdaq: VRCA) has appointed Dr. Gavin Corcoran to its Board of Directors. Dr. Corcoran, currently Chief Development Officer at Formation Bio, brings extensive pharmaceutical experience from leadership positions at Sio Gene Therapies, Allergan, and Stiefel Laboratories.

The appointment comes at a important time as Verrica experiences growing commercial success with YCANTH®, its treatment for molluscum contagiosum, which is gaining increased adoption among dermatologists and pediatricians. The company aims to leverage Dr. Corcoran's expertise in developing innovative medicines and executing strategic transactions to advance its late-stage dermatology pipeline.

Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's President and CEO, Jayson Rieger, PhD, MBA, will engage in a fireside chat during the event.

The virtual presentation is scheduled for Tuesday, April 8, 2025, at 1:30 pm ET. Interested participants can access the live webcast through a provided link or via the Investors/Presentations & Events section on Verrica's website. The webcast recording will remain available for 90 days after the event, which runs from April 7-10, 2025.

Verrica Pharmaceuticals (Nasdaq: VRCA) has appointed Noah L. Rosenberg, M.D. as Chief Medical Officer. Dr. Rosenberg brings over 30 years of clinical and therapeutic development experience, with multiple global drug approvals including dermatology treatments.

Dr. Rosenberg succeeds Gary Goldenberg, who will continue as a strategic advisor after overseeing the FDA approval of YCANTH® for molluscum contagiosum treatment. In his new role, Rosenberg will focus on establishing YCANTH® as the standard care for molluscum contagiosum and advancing clinical programs in basal cell carcinoma and common warts.

As part of his appointment, Dr. Rosenberg received an inducement grant of stock options to purchase 325,000 shares at $0.5221 per share, vesting over four years with initial 1/8th vesting after six months.